Nci h23

MDA-MB-231 cells were purchased from the American Type Culture Collection (Rockville, MD). NCI-H23, A-498, SNU-423, HeLa, COLO 205, and Calu-3 cells were purchased from the Korean Cell Line Bank (Seoul, Korea). HEK293A cells were purchased from Invitrogen (Carlsbad, CA). MDA-MB-231, NCI-H23, A-498, SNU-423, and COLO 205 cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in 5% CO₂. HeLa cells were grown in modified Eagle’s medium (MEM; HyClone, Logan, UT) supplemented with 10% FBS, penicillin, and streptomycin. HEK293A and Calu-3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; HyClone) supplemented with 10% FBS, penicillin, and streptomycin. CXCL12 (#300-28A) was purchased from PeproTech (London, UK). Histamine (#H7250) was purchased from Sigma‒Aldrich (St. Louis, MO). AMD3100 (#HY10046), U73122 (#HY-13419), and U0126 (#HY-12031) were purchased from MedChemExpress (Monmouth Junction, NJ). Pyrilamine (#0660) and PTX (#3097) were purchased from Tocris Bioscience (Ellisville, MO). YM254890 (#AG-CN2-0509-MC05) was purchased from AdipoGen Life Sciences (San Diego, CA).

Human cervical cancer HeLa cells, as well as non-small cell lung cancer NCI-H23, NCI-H1703, NCI-H358, and Calu-3 cells, were purchased from the Korean Cell Line Bank (Seoul, Korea) or KRIBB Cell Line Bank (Daejeon, Korea). The lung cancer cell lines YL01, YL03, YL05 (EGFR exon19del), and YL08 (EGFR wild-type/ALK mutation-positive), each derived from a different patient, were provided by the Yonsei University College of Medicine, Seoul, Korea. Patient characteristics and treatments were previously described^{19 (link)}. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) or RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Cells were transfected with plasmids using Turbofect (Thermo Scientific, Rockford, IL, USA) and with siRNAs (20–40 nM) by electroporation (Neon, Invitrogen) according to the manufacturer’s instructions. The siRNAs used in this study were purchased from Bioneer Corporation (Daejeon, Korea). The target sequences were as follows: siJNK1 #1, 5′-CUGGUAUGAUCCUUCUGAA-3′; siJNK1 #2, 5′-GUCACACCUGGAAACCUGA-3′; and siScrambled, 5′-CCUACGCCACCAAUUUCGU-3′.

Two human non-small cell lung cancer cell lines, A549 and NCI-H23, were used in this study, and were obtained from the Korean Cell Line Bank (Seoul, Korea). These cell lines were maintained in RPMI media supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY), 2 mM L-glutamine, 100 μg/ml streptomycin, and 100 U/ml penicillin. The NK-92 cell line was obtained from the American Type Culture Collection (Rockville, MD, USA) and maintained in alpha-Minimum Essential Modified medium supplemented with 12.5% (v/v) fetal bovine serum, 12.5% (v/v) horse serum, 2 mM L-glutamine,0.1 mM 2-mercaptoethanol, 200 U/mL of recombinant human interleukin-2, 100 μg/mL streptomycin, and 100U/mL penicillin. All cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂.Three HDAC inhibitors, apicidin, suberoylanilide hydroxamic acid (SAHA; vorinostat) and tricostatin A (TSA), two ATM-ATR inhibitors, caffeine, and KU-55933, cycloheximide (CHX) were purchased from Sigma-Aldrich (St. Louis, MO, USA). To irradiate cancer cells, we used a ClinaciX Linear Accelerator (Varian Medical Systems, Inc. Palo Alto, CA, USA) with the assistance of Dr. Jiho Nam (Pusan National University Yangsan Hospital).